Evaluation of Esophageal Cancers Using Fluorine-18-Fluorodeoxyglucose PET
To evaluate glucose metabolism in esophageal cancer, 48 patients were studied using PET with 18F-2-fluoro-2-deoxy-D-glucose (FDG). After transmission scans were obtained, 18F-FDG (148 MBq) was administered intravenously. In 11 patients, a dynamic study was performed to evaluate glucose metabolism. U...
Gespeichert in:
| Veröffentlicht in: | The Journal of nuclear medicine (1978) 1998-06, Vol.39 (6), p.1002-1007 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1007 |
|---|---|
| container_issue | 6 |
| container_start_page | 1002 |
| container_title | The Journal of nuclear medicine (1978) |
| container_volume | 39 |
| creator | Fukunaga, Toru Okazumi, Shinichi Koide, Yoshio Isono, Kaichi Imazeki, Keiko |
| description | To evaluate glucose metabolism in esophageal cancer, 48 patients were studied using PET with 18F-2-fluoro-2-deoxy-D-glucose (FDG).
After transmission scans were obtained, 18F-FDG (148 MBq) was administered intravenously. In 11 patients, a dynamic study was performed to evaluate glucose metabolism. Using the changes of radioactivity in both plasma and tumor, rate constants (k1-k4) defined in the metabolic model for 18F-FDG were calculated. In 48 patients, static PET scans of the tumor (5-min scans) were obtained 60 min after administration. Fluorine-18-FDG activity within each tumor was corrected for physical decay and normalized by dose administration and patient weight to produce a standardized uptake value (SUV).
Both the k3 value (n = 11) reflecting hexokinase activity and SUV (n = 13) were well correlated with hexokinase activity from the resected specimen (p < 0.05). Forty-seven of 48 patients before treatment revealed SUV greater than 2.0, but 10 normal control subjects and 1 esophageal benign tumor revealed less than 2.0 (accuracy rate 98.3%). Although clinicopathological findings did not correlate with SUV, except for two patients with carcinosarcoma, 23 patients with an SUV greater than 7.0 had a poor prognosis compared with 25 patients with SUVs less than 7.0.
These findings suggest that 18F-FDG PET may be useful in distinguishing malignant tumors from benign lesions and in the preoperative evaluation of the prognostic factor. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_79934750</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>30242662</sourcerecordid><originalsourceid>FETCH-LOGICAL-h294t-dad567d587e3863c9dd704f4ce7b095646c39509707703923edfc1e824f316bd3</originalsourceid><addsrcrecordid>eNpd0F1LwzAUBuAgypzTnyAUEb0q5KNJmksZnQ4GerFdlyxJP0bazGRR9--trnjh1TlwHl4O7xmYIkpoShnj52AKEUMppZBegqsQdhBCluf5BEwEw5wQMgXL4kPaKA-t6xNXJUVw-0bWRtpkLntlfEg2oe3rZGGj821vUpSnv7vTxn0daxuVCyZ5K9bX4KKSNpibcc7AZlGs5y_p6vV5OX9apQ0W2SHVUlPGNc25ITkjSmjNYVZlyvAtFJRlTBFBoeCQc0gEJkZXCpkcZxVBbKvJDDyccvfevUcTDmXXBmWslb1xMZRcCJJxCgd49w_uXPT98FuJkUA0Izka0O2I4rYzutz7tpP-WI4FDff78S6DkrbyQytt-GMYMzGkDOzxxJq2bj5bb8o-Kmuk_8nc9R0RJSsRhJh8AzfZexc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219154381</pqid></control><display><type>article</type><title>Evaluation of Esophageal Cancers Using Fluorine-18-Fluorodeoxyglucose PET</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Fukunaga, Toru ; Okazumi, Shinichi ; Koide, Yoshio ; Isono, Kaichi ; Imazeki, Keiko</creator><creatorcontrib>Fukunaga, Toru ; Okazumi, Shinichi ; Koide, Yoshio ; Isono, Kaichi ; Imazeki, Keiko</creatorcontrib><description>To evaluate glucose metabolism in esophageal cancer, 48 patients were studied using PET with 18F-2-fluoro-2-deoxy-D-glucose (FDG).
After transmission scans were obtained, 18F-FDG (148 MBq) was administered intravenously. In 11 patients, a dynamic study was performed to evaluate glucose metabolism. Using the changes of radioactivity in both plasma and tumor, rate constants (k1-k4) defined in the metabolic model for 18F-FDG were calculated. In 48 patients, static PET scans of the tumor (5-min scans) were obtained 60 min after administration. Fluorine-18-FDG activity within each tumor was corrected for physical decay and normalized by dose administration and patient weight to produce a standardized uptake value (SUV).
Both the k3 value (n = 11) reflecting hexokinase activity and SUV (n = 13) were well correlated with hexokinase activity from the resected specimen (p < 0.05). Forty-seven of 48 patients before treatment revealed SUV greater than 2.0, but 10 normal control subjects and 1 esophageal benign tumor revealed less than 2.0 (accuracy rate 98.3%). Although clinicopathological findings did not correlate with SUV, except for two patients with carcinosarcoma, 23 patients with an SUV greater than 7.0 had a poor prognosis compared with 25 patients with SUVs less than 7.0.
These findings suggest that 18F-FDG PET may be useful in distinguishing malignant tumors from benign lesions and in the preoperative evaluation of the prognostic factor.</description><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><identifier>PMID: 9627333</identifier><identifier>CODEN: JNMEAQ</identifier><language>eng</language><publisher>Reston, VA: Soc Nuclear Med</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Esophageal Neoplasms - diagnostic imaging ; Esophageal Neoplasms - metabolism ; Esophageal Neoplasms - pathology ; Esophagus ; Female ; Fluorodeoxyglucose F18 ; Gastroenterology. Liver. Pancreas. Abdomen ; Glucose - metabolism ; Hexokinase - metabolism ; Humans ; Male ; Medical sciences ; Middle Aged ; Prognosis ; Radiopharmaceuticals ; Tomography, Emission-Computed ; Tumors</subject><ispartof>The Journal of nuclear medicine (1978), 1998-06, Vol.39 (6), p.1002-1007</ispartof><rights>1998 INIST-CNRS</rights><rights>Copyright Society of Nuclear Medicine Jun 1998</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2269813$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9627333$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fukunaga, Toru</creatorcontrib><creatorcontrib>Okazumi, Shinichi</creatorcontrib><creatorcontrib>Koide, Yoshio</creatorcontrib><creatorcontrib>Isono, Kaichi</creatorcontrib><creatorcontrib>Imazeki, Keiko</creatorcontrib><title>Evaluation of Esophageal Cancers Using Fluorine-18-Fluorodeoxyglucose PET</title><title>The Journal of nuclear medicine (1978)</title><addtitle>J Nucl Med</addtitle><description>To evaluate glucose metabolism in esophageal cancer, 48 patients were studied using PET with 18F-2-fluoro-2-deoxy-D-glucose (FDG).
After transmission scans were obtained, 18F-FDG (148 MBq) was administered intravenously. In 11 patients, a dynamic study was performed to evaluate glucose metabolism. Using the changes of radioactivity in both plasma and tumor, rate constants (k1-k4) defined in the metabolic model for 18F-FDG were calculated. In 48 patients, static PET scans of the tumor (5-min scans) were obtained 60 min after administration. Fluorine-18-FDG activity within each tumor was corrected for physical decay and normalized by dose administration and patient weight to produce a standardized uptake value (SUV).
Both the k3 value (n = 11) reflecting hexokinase activity and SUV (n = 13) were well correlated with hexokinase activity from the resected specimen (p < 0.05). Forty-seven of 48 patients before treatment revealed SUV greater than 2.0, but 10 normal control subjects and 1 esophageal benign tumor revealed less than 2.0 (accuracy rate 98.3%). Although clinicopathological findings did not correlate with SUV, except for two patients with carcinosarcoma, 23 patients with an SUV greater than 7.0 had a poor prognosis compared with 25 patients with SUVs less than 7.0.
These findings suggest that 18F-FDG PET may be useful in distinguishing malignant tumors from benign lesions and in the preoperative evaluation of the prognostic factor.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Esophageal Neoplasms - diagnostic imaging</subject><subject>Esophageal Neoplasms - metabolism</subject><subject>Esophageal Neoplasms - pathology</subject><subject>Esophagus</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Glucose - metabolism</subject><subject>Hexokinase - metabolism</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Prognosis</subject><subject>Radiopharmaceuticals</subject><subject>Tomography, Emission-Computed</subject><subject>Tumors</subject><issn>0161-5505</issn><issn>1535-5667</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpd0F1LwzAUBuAgypzTnyAUEb0q5KNJmksZnQ4GerFdlyxJP0bazGRR9--trnjh1TlwHl4O7xmYIkpoShnj52AKEUMppZBegqsQdhBCluf5BEwEw5wQMgXL4kPaKA-t6xNXJUVw-0bWRtpkLntlfEg2oe3rZGGj821vUpSnv7vTxn0daxuVCyZ5K9bX4KKSNpibcc7AZlGs5y_p6vV5OX9apQ0W2SHVUlPGNc25ITkjSmjNYVZlyvAtFJRlTBFBoeCQc0gEJkZXCpkcZxVBbKvJDDyccvfevUcTDmXXBmWslb1xMZRcCJJxCgd49w_uXPT98FuJkUA0Izka0O2I4rYzutz7tpP-WI4FDff78S6DkrbyQytt-GMYMzGkDOzxxJq2bj5bb8o-Kmuk_8nc9R0RJSsRhJh8AzfZexc</recordid><startdate>19980601</startdate><enddate>19980601</enddate><creator>Fukunaga, Toru</creator><creator>Okazumi, Shinichi</creator><creator>Koide, Yoshio</creator><creator>Isono, Kaichi</creator><creator>Imazeki, Keiko</creator><general>Soc Nuclear Med</general><general>Society of Nuclear Medicine</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>4T-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>19980601</creationdate><title>Evaluation of Esophageal Cancers Using Fluorine-18-Fluorodeoxyglucose PET</title><author>Fukunaga, Toru ; Okazumi, Shinichi ; Koide, Yoshio ; Isono, Kaichi ; Imazeki, Keiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h294t-dad567d587e3863c9dd704f4ce7b095646c39509707703923edfc1e824f316bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Esophageal Neoplasms - diagnostic imaging</topic><topic>Esophageal Neoplasms - metabolism</topic><topic>Esophageal Neoplasms - pathology</topic><topic>Esophagus</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Glucose - metabolism</topic><topic>Hexokinase - metabolism</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Prognosis</topic><topic>Radiopharmaceuticals</topic><topic>Tomography, Emission-Computed</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fukunaga, Toru</creatorcontrib><creatorcontrib>Okazumi, Shinichi</creatorcontrib><creatorcontrib>Koide, Yoshio</creatorcontrib><creatorcontrib>Isono, Kaichi</creatorcontrib><creatorcontrib>Imazeki, Keiko</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of nuclear medicine (1978)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fukunaga, Toru</au><au>Okazumi, Shinichi</au><au>Koide, Yoshio</au><au>Isono, Kaichi</au><au>Imazeki, Keiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of Esophageal Cancers Using Fluorine-18-Fluorodeoxyglucose PET</atitle><jtitle>The Journal of nuclear medicine (1978)</jtitle><addtitle>J Nucl Med</addtitle><date>1998-06-01</date><risdate>1998</risdate><volume>39</volume><issue>6</issue><spage>1002</spage><epage>1007</epage><pages>1002-1007</pages><issn>0161-5505</issn><eissn>1535-5667</eissn><coden>JNMEAQ</coden><abstract>To evaluate glucose metabolism in esophageal cancer, 48 patients were studied using PET with 18F-2-fluoro-2-deoxy-D-glucose (FDG).
After transmission scans were obtained, 18F-FDG (148 MBq) was administered intravenously. In 11 patients, a dynamic study was performed to evaluate glucose metabolism. Using the changes of radioactivity in both plasma and tumor, rate constants (k1-k4) defined in the metabolic model for 18F-FDG were calculated. In 48 patients, static PET scans of the tumor (5-min scans) were obtained 60 min after administration. Fluorine-18-FDG activity within each tumor was corrected for physical decay and normalized by dose administration and patient weight to produce a standardized uptake value (SUV).
Both the k3 value (n = 11) reflecting hexokinase activity and SUV (n = 13) were well correlated with hexokinase activity from the resected specimen (p < 0.05). Forty-seven of 48 patients before treatment revealed SUV greater than 2.0, but 10 normal control subjects and 1 esophageal benign tumor revealed less than 2.0 (accuracy rate 98.3%). Although clinicopathological findings did not correlate with SUV, except for two patients with carcinosarcoma, 23 patients with an SUV greater than 7.0 had a poor prognosis compared with 25 patients with SUVs less than 7.0.
These findings suggest that 18F-FDG PET may be useful in distinguishing malignant tumors from benign lesions and in the preoperative evaluation of the prognostic factor.</abstract><cop>Reston, VA</cop><pub>Soc Nuclear Med</pub><pmid>9627333</pmid><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0161-5505 |
| ispartof | The Journal of nuclear medicine (1978), 1998-06, Vol.39 (6), p.1002-1007 |
| issn | 0161-5505 1535-5667 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79934750 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Biological and medical sciences Esophageal Neoplasms - diagnostic imaging Esophageal Neoplasms - metabolism Esophageal Neoplasms - pathology Esophagus Female Fluorodeoxyglucose F18 Gastroenterology. Liver. Pancreas. Abdomen Glucose - metabolism Hexokinase - metabolism Humans Male Medical sciences Middle Aged Prognosis Radiopharmaceuticals Tomography, Emission-Computed Tumors |
| title | Evaluation of Esophageal Cancers Using Fluorine-18-Fluorodeoxyglucose PET |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T06%3A49%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20Esophageal%20Cancers%20Using%20Fluorine-18-Fluorodeoxyglucose%20PET&rft.jtitle=The%20Journal%20of%20nuclear%20medicine%20(1978)&rft.au=Fukunaga,%20Toru&rft.date=1998-06-01&rft.volume=39&rft.issue=6&rft.spage=1002&rft.epage=1007&rft.pages=1002-1007&rft.issn=0161-5505&rft.eissn=1535-5667&rft.coden=JNMEAQ&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E30242662%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219154381&rft_id=info:pmid/9627333&rfr_iscdi=true |